nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—CACNA1I—NCAM1 interactions—NCAM1—peripheral nervous system neoplasm	0.0136	0.0995	CbGpPWpGaD
Methsuximide—Proteinuria—Isotretinoin—peripheral nervous system neoplasm	0.0108	0.0126	CcSEcCtD
Methsuximide—Aggression—Isotretinoin—peripheral nervous system neoplasm	0.0108	0.0126	CcSEcCtD
Methsuximide—Protein urine present—Tretinoin—peripheral nervous system neoplasm	0.0107	0.0124	CcSEcCtD
Methsuximide—Protein urine present—Isotretinoin—peripheral nervous system neoplasm	0.0107	0.0124	CcSEcCtD
Methsuximide—CACNA1G—NCAM1 interactions—NCAM1—peripheral nervous system neoplasm	0.01	0.0733	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM1 interactions—NCAM1—peripheral nervous system neoplasm	0.00971	0.071	CbGpPWpGaD
Methsuximide—Photophobia—Isotretinoin—peripheral nervous system neoplasm	0.00891	0.0104	CcSEcCtD
Methsuximide—Photophobia—Tretinoin—peripheral nervous system neoplasm	0.00891	0.0104	CcSEcCtD
Methsuximide—Proteinuria—Alitretinoin—peripheral nervous system neoplasm	0.00819	0.00952	CcSEcCtD
Methsuximide—Aggression—Alitretinoin—peripheral nervous system neoplasm	0.00819	0.00952	CcSEcCtD
Methsuximide—Protein urine present—Alitretinoin—peripheral nervous system neoplasm	0.00807	0.00938	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NCAM1—peripheral nervous system neoplasm	0.008	0.0585	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—COX2—peripheral nervous system neoplasm	0.00773	0.0565	CbGpPWpGaD
Methsuximide—Photophobia—Alitretinoin—peripheral nervous system neoplasm	0.00675	0.00785	CcSEcCtD
Methsuximide—Psychotic disorder—Tretinoin—peripheral nervous system neoplasm	0.00673	0.00782	CcSEcCtD
Methsuximide—Psychotic disorder—Isotretinoin—peripheral nervous system neoplasm	0.00673	0.00782	CcSEcCtD
Methsuximide—Irritability—Tretinoin—peripheral nervous system neoplasm	0.00658	0.00764	CcSEcCtD
Methsuximide—Irritability—Isotretinoin—peripheral nervous system neoplasm	0.00658	0.00764	CcSEcCtD
Methsuximide—Hiccups—Cisplatin—peripheral nervous system neoplasm	0.00613	0.00712	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NCAM1—peripheral nervous system neoplasm	0.0059	0.0431	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NCAM1—peripheral nervous system neoplasm	0.00571	0.0418	CbGpPWpGaD
Methsuximide—Pancytopenia—Topotecan—peripheral nervous system neoplasm	0.0057	0.00663	CcSEcCtD
Methsuximide—Pancytopenia—Melphalan—peripheral nervous system neoplasm	0.00558	0.00649	CcSEcCtD
Methsuximide—Weight decreased—Tretinoin—peripheral nervous system neoplasm	0.00539	0.00626	CcSEcCtD
Methsuximide—Weight decreased—Isotretinoin—peripheral nervous system neoplasm	0.00539	0.00626	CcSEcCtD
Methsuximide—Drowsiness—Isotretinoin—peripheral nervous system neoplasm	0.00531	0.00617	CcSEcCtD
Methsuximide—Drowsiness—Tretinoin—peripheral nervous system neoplasm	0.00531	0.00617	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Tretinoin—peripheral nervous system neoplasm	0.00526	0.00612	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Isotretinoin—peripheral nervous system neoplasm	0.00526	0.00612	CcSEcCtD
Methsuximide—Psychotic disorder—Alitretinoin—peripheral nervous system neoplasm	0.0051	0.00593	CcSEcCtD
Methsuximide—Haematuria—Tretinoin—peripheral nervous system neoplasm	0.00506	0.00588	CcSEcCtD
Methsuximide—Haematuria—Isotretinoin—peripheral nervous system neoplasm	0.00506	0.00588	CcSEcCtD
Methsuximide—Irritability—Alitretinoin—peripheral nervous system neoplasm	0.00498	0.00579	CcSEcCtD
Methsuximide—Ataxia—Vincristine—peripheral nervous system neoplasm	0.00473	0.0055	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—CNTN6—peripheral nervous system neoplasm	0.0047	0.0343	CbGpPWpGaD
Methsuximide—Pancytopenia—Dactinomycin—peripheral nervous system neoplasm	0.00462	0.00537	CcSEcCtD
Methsuximide—Erythema multiforme—Isotretinoin—peripheral nervous system neoplasm	0.00451	0.00524	CcSEcCtD
Methsuximide—Erythema multiforme—Tretinoin—peripheral nervous system neoplasm	0.00451	0.00524	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Dactinomycin—peripheral nervous system neoplasm	0.0043	0.005	CcSEcCtD
Methsuximide—Irritability—Cisplatin—peripheral nervous system neoplasm	0.00425	0.00494	CcSEcCtD
Methsuximide—Pancytopenia—Vincristine—peripheral nervous system neoplasm	0.00413	0.0048	CcSEcCtD
Methsuximide—Weight decreased—Alitretinoin—peripheral nervous system neoplasm	0.00408	0.00475	CcSEcCtD
Methsuximide—Tension—Tretinoin—peripheral nervous system neoplasm	0.00407	0.00473	CcSEcCtD
Methsuximide—Tension—Isotretinoin—peripheral nervous system neoplasm	0.00407	0.00473	CcSEcCtD
Methsuximide—Nervousness—Tretinoin—peripheral nervous system neoplasm	0.00403	0.00468	CcSEcCtD
Methsuximide—Nervousness—Isotretinoin—peripheral nervous system neoplasm	0.00403	0.00468	CcSEcCtD
Methsuximide—Drowsiness—Alitretinoin—peripheral nervous system neoplasm	0.00402	0.00468	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Alitretinoin—peripheral nervous system neoplasm	0.00399	0.00464	CcSEcCtD
Methsuximide—Weight decreased—Vincristine—peripheral nervous system neoplasm	0.00393	0.00457	CcSEcCtD
Methsuximide—Vision blurred—Isotretinoin—peripheral nervous system neoplasm	0.00391	0.00455	CcSEcCtD
Methsuximide—Vision blurred—Tretinoin—peripheral nervous system neoplasm	0.00391	0.00455	CcSEcCtD
Methsuximide—Haematuria—Alitretinoin—peripheral nervous system neoplasm	0.00384	0.00446	CcSEcCtD
Methsuximide—Leukopenia—Topotecan—peripheral nervous system neoplasm	0.00374	0.00435	CcSEcCtD
Methsuximide—Erythema multiforme—Dactinomycin—peripheral nervous system neoplasm	0.00368	0.00428	CcSEcCtD
Methsuximide—Leukopenia—Melphalan—peripheral nervous system neoplasm	0.00367	0.00426	CcSEcCtD
Methsuximide—Pancytopenia—Cisplatin—peripheral nervous system neoplasm	0.00365	0.00424	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—PTPN11—peripheral nervous system neoplasm	0.00353	0.0258	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—CNTN6—peripheral nervous system neoplasm	0.00346	0.0253	CbGpPWpGaD
Methsuximide—Erythema multiforme—Alitretinoin—peripheral nervous system neoplasm	0.00341	0.00397	CcSEcCtD
Methsuximide—Confusional state—Isotretinoin—peripheral nervous system neoplasm	0.00341	0.00397	CcSEcCtD
Methsuximide—Confusional state—Tretinoin—peripheral nervous system neoplasm	0.00341	0.00397	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—CNTN6—peripheral nervous system neoplasm	0.00335	0.0245	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.00335	0.0245	CbGpPWpGaD
Methsuximide—Pancytopenia—Etoposide—peripheral nervous system neoplasm	0.00334	0.00389	CcSEcCtD
Methsuximide—Anorexia—Topotecan—peripheral nervous system neoplasm	0.00325	0.00378	CcSEcCtD
Methsuximide—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.00323	0.00375	CcSEcCtD
Methsuximide—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.00323	0.00375	CcSEcCtD
Methsuximide—Anorexia—Melphalan—peripheral nervous system neoplasm	0.00319	0.0037	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—peripheral nervous system neoplasm	0.00315	0.00366	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Etoposide—peripheral nervous system neoplasm	0.00311	0.00362	CcSEcCtD
Methsuximide—Tension—Alitretinoin—peripheral nervous system neoplasm	0.00309	0.00359	CcSEcCtD
Methsuximide—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.00306	0.00356	CcSEcCtD
Methsuximide—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.00306	0.00356	CcSEcCtD
Methsuximide—Nervousness—Alitretinoin—peripheral nervous system neoplasm	0.00305	0.00355	CcSEcCtD
Methsuximide—Leukopenia—Dactinomycin—peripheral nervous system neoplasm	0.00304	0.00353	CcSEcCtD
Methsuximide—Somnolence—Tretinoin—peripheral nervous system neoplasm	0.00301	0.0035	CcSEcCtD
Methsuximide—Somnolence—Isotretinoin—peripheral nervous system neoplasm	0.00301	0.0035	CcSEcCtD
Methsuximide—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.00297	0.00345	CcSEcCtD
Methsuximide—Vision blurred—Alitretinoin—peripheral nervous system neoplasm	0.00296	0.00344	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.00295	0.00343	CcSEcCtD
Methsuximide—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00294	0.00342	CcSEcCtD
Methsuximide—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00294	0.00342	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00292	0.0034	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00292	0.0034	CcSEcCtD
Methsuximide—Constipation—Topotecan—peripheral nervous system neoplasm	0.00292	0.00339	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—peripheral nervous system neoplasm	0.00291	0.00339	CcSEcCtD
Methsuximide—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.00291	0.00338	CcSEcCtD
Methsuximide—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.0029	0.00337	CcSEcCtD
Methsuximide—Constipation—Tretinoin—peripheral nervous system neoplasm	0.0029	0.00337	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.00289	0.00335	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—GNAS—peripheral nervous system neoplasm	0.00285	0.0208	CbGpPWpGaD
Methsuximide—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.00281	0.00327	CcSEcCtD
Methsuximide—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00279	0.00324	CcSEcCtD
Methsuximide—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.00279	0.00324	CcSEcCtD
Methsuximide—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.00279	0.00324	CcSEcCtD
Methsuximide—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00277	0.00322	CcSEcCtD
Methsuximide—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00277	0.00322	CcSEcCtD
Methsuximide—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.00271	0.00315	CcSEcCtD
Methsuximide—Urticaria—Topotecan—peripheral nervous system neoplasm	0.00271	0.00315	CcSEcCtD
Methsuximide—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.0027	0.00314	CcSEcCtD
Methsuximide—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00269	0.00313	CcSEcCtD
Methsuximide—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00269	0.00313	CcSEcCtD
Methsuximide—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00268	0.00311	CcSEcCtD
Methsuximide—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00268	0.00311	CcSEcCtD
Methsuximide—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.00267	0.0031	CcSEcCtD
Methsuximide—Urticaria—Melphalan—peripheral nervous system neoplasm	0.00265	0.00309	CcSEcCtD
Methsuximide—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.00264	0.00307	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—PTPN11—peripheral nervous system neoplasm	0.00261	0.0191	CbGpPWpGaD
Methsuximide—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.00259	0.00301	CcSEcCtD
Methsuximide—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.00252	0.00293	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—PTPN11—peripheral nervous system neoplasm	0.00252	0.0185	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.00247	0.0181	CbGpPWpGaD
Methsuximide—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.00245	0.00284	CcSEcCtD
Methsuximide—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.00241	0.0028	CcSEcCtD
Methsuximide—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.0024	0.00279	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—CNTN6—peripheral nervous system neoplasm	0.00239	0.0175	CbGpPWpGaD
Methsuximide—Anorexia—Vincristine—peripheral nervous system neoplasm	0.00236	0.00274	CcSEcCtD
Methsuximide—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00234	0.00271	CcSEcCtD
Methsuximide—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00232	0.0027	CcSEcCtD
Methsuximide—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00232	0.00269	CcSEcCtD
Methsuximide—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00232	0.00269	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.00229	0.0168	CbGpPWpGaD
Methsuximide—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00229	0.00266	CcSEcCtD
Methsuximide—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00228	0.00265	CcSEcCtD
Methsuximide—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.00228	0.00265	CcSEcCtD
Methsuximide—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00226	0.00263	CcSEcCtD
Methsuximide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00226	0.00262	CcSEcCtD
Methsuximide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00224	0.0026	CcSEcCtD
Methsuximide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00224	0.0026	CcSEcCtD
Methsuximide—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00224	0.0026	CcSEcCtD
Methsuximide—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.00223	0.00259	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00222	0.00258	CcSEcCtD
Methsuximide—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.0022	0.00255	CcSEcCtD
Methsuximide—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00219	0.00255	CcSEcCtD
Methsuximide—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00219	0.00254	CcSEcCtD
Methsuximide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00217	0.00252	CcSEcCtD
Methsuximide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Rash—Topotecan—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—peripheral nervous system neoplasm	0.00215	0.0025	CcSEcCtD
Methsuximide—Headache—Topotecan—peripheral nervous system neoplasm	0.00214	0.00249	CcSEcCtD
Methsuximide—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00213	0.00248	CcSEcCtD
Methsuximide—Rash—Tretinoin—peripheral nervous system neoplasm	0.00213	0.00248	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00213	0.00248	CcSEcCtD
Methsuximide—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00213	0.00248	CcSEcCtD
Methsuximide—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00213	0.00248	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NRAS—peripheral nervous system neoplasm	0.00213	0.0155	CbGpPWpGaD
Methsuximide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00212	0.00247	CcSEcCtD
Methsuximide—Headache—Tretinoin—peripheral nervous system neoplasm	0.00212	0.00247	CcSEcCtD
Methsuximide—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.00247	CcSEcCtD
Methsuximide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00211	0.00246	CcSEcCtD
Methsuximide—Constipation—Vincristine—peripheral nervous system neoplasm	0.00211	0.00246	CcSEcCtD
Methsuximide—Rash—Melphalan—peripheral nervous system neoplasm	0.00211	0.00245	CcSEcCtD
Methsuximide—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00211	0.00245	CcSEcCtD
Methsuximide—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.0021	0.00244	CcSEcCtD
Methsuximide—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.00208	0.00242	CcSEcCtD
Methsuximide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00204	0.00237	CcSEcCtD
Methsuximide—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00203	0.00236	CcSEcCtD
Methsuximide—Nausea—Topotecan—peripheral nervous system neoplasm	0.00203	0.00236	CcSEcCtD
Methsuximide—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00202	0.00235	CcSEcCtD
Methsuximide—Confusional state—Etoposide—peripheral nervous system neoplasm	0.00202	0.00235	CcSEcCtD
Methsuximide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00201	0.00234	CcSEcCtD
Methsuximide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00201	0.00234	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.00199	0.00231	CcSEcCtD
Methsuximide—Nausea—Melphalan—peripheral nervous system neoplasm	0.00199	0.00231	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.00195	0.00227	CcSEcCtD
Methsuximide—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00195	0.00227	CcSEcCtD
Methsuximide—Anorexia—Etoposide—peripheral nervous system neoplasm	0.00191	0.00222	CcSEcCtD
Methsuximide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.0019	0.00221	CcSEcCtD
Methsuximide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00189	0.0022	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—peripheral nervous system neoplasm	0.00189	0.0138	CbGpPWpGaD
Methsuximide—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00189	0.00219	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.00188	0.00218	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.00181	0.0021	CcSEcCtD
Methsuximide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.0018	0.00209	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.00179	0.00208	CcSEcCtD
Methsuximide—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00178	0.00207	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.00176	0.00205	CcSEcCtD
Methsuximide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00176	0.00205	CcSEcCtD
Methsuximide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00176	0.00204	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.00175	0.00203	CcSEcCtD
Methsuximide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.00174	0.00203	CcSEcCtD
Methsuximide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.00174	0.00202	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.00173	0.00202	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00173	0.00201	CcSEcCtD
Methsuximide—Constipation—Etoposide—peripheral nervous system neoplasm	0.00171	0.00199	CcSEcCtD
Methsuximide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.0017	0.00197	CcSEcCtD
Methsuximide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00169	0.00197	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.00169	0.0124	CbGpPWpGaD
Methsuximide—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.00168	0.00195	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.00165	0.00192	CcSEcCtD
Methsuximide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.00165	0.00192	CcSEcCtD
Methsuximide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00164	0.00191	CcSEcCtD
Methsuximide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00164	0.0019	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—NCAM1—peripheral nervous system neoplasm	0.00164	0.012	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.00164	0.012	CbGpPWpGaD
Methsuximide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00164	0.0019	CcSEcCtD
Methsuximide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00163	0.0019	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.00163	0.00189	CcSEcCtD
Methsuximide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00162	0.00188	CcSEcCtD
Methsuximide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00162	0.00188	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.00161	0.00188	CcSEcCtD
Methsuximide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00187	CcSEcCtD
Methsuximide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00159	0.00185	CcSEcCtD
Methsuximide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00158	0.00184	CcSEcCtD
Methsuximide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00157	0.00183	CcSEcCtD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NRAS—peripheral nervous system neoplasm	0.00157	0.0115	CbGpPWpGaD
Methsuximide—Rash—Vincristine—peripheral nervous system neoplasm	0.00156	0.00181	CcSEcCtD
Methsuximide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00156	0.00181	CcSEcCtD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—peripheral nervous system neoplasm	0.00155	0.0114	CbGpPWpGaD
Methsuximide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.00155	0.00181	CcSEcCtD
Methsuximide—Headache—Vincristine—peripheral nervous system neoplasm	0.00155	0.0018	CcSEcCtD
Methsuximide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00152	0.00177	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NRAS—peripheral nervous system neoplasm	0.00152	0.0111	CbGpPWpGaD
Methsuximide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.0015	0.00174	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.00149	0.00174	CcSEcCtD
Methsuximide—Nausea—Vincristine—peripheral nervous system neoplasm	0.00147	0.00171	CcSEcCtD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CASP3—peripheral nervous system neoplasm	0.00142	0.0104	CbGpPWpGaD
Methsuximide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00139	0.00162	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.00138	0.00161	CcSEcCtD
Methsuximide—Rash—Cisplatin—peripheral nervous system neoplasm	0.00138	0.0016	CcSEcCtD
Methsuximide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00138	0.0016	CcSEcCtD
Methsuximide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00137	0.00159	CcSEcCtD
Methsuximide—Tension—Epirubicin—peripheral nervous system neoplasm	0.00135	0.00157	CcSEcCtD
Methsuximide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00135	0.00986	CbGpPWpGaD
Methsuximide—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.00134	0.00155	CcSEcCtD
Methsuximide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00132	0.00154	CcSEcCtD
Methsuximide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.0013	0.00151	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.0013	0.00151	CcSEcCtD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—peripheral nervous system neoplasm	0.00128	0.00937	CbGpPWpGaD
Methsuximide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00127	0.00148	CcSEcCtD
Methsuximide—Rash—Etoposide—peripheral nervous system neoplasm	0.00126	0.00147	CcSEcCtD
Methsuximide—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00126	0.00147	CcSEcCtD
Methsuximide—Headache—Etoposide—peripheral nervous system neoplasm	0.00125	0.00146	CcSEcCtD
Methsuximide—Tension—Doxorubicin—peripheral nervous system neoplasm	0.00125	0.00145	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.00124	0.00144	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.00123	0.00143	CcSEcCtD
Methsuximide—CACNA1G—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.00121	0.00882	CbGpPWpGaD
Methsuximide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.0012	0.00139	CcSEcCtD
Methsuximide—Nausea—Etoposide—peripheral nervous system neoplasm	0.00119	0.00138	CcSEcCtD
Methsuximide—CACNA1H—Developmental Biology—NCAM1—peripheral nervous system neoplasm	0.00117	0.00854	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—peripheral nervous system neoplasm	0.00115	0.00838	CbGpPWpGaD
Methsuximide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.00114	0.00132	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.00113	0.00132	CcSEcCtD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—peripheral nervous system neoplasm	0.00111	0.00812	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—peripheral nervous system neoplasm	0.0011	0.00801	CbGpPWpGaD
Methsuximide—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.00107	0.00124	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.00105	0.00122	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.00102	0.00118	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.00101	0.00741	CbGpPWpGaD
Methsuximide—Ketazolam—ABCB1—peripheral nervous system neoplasm	0.00101	0.337	CrCbGaD
Methsuximide—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000998	0.00116	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.00099	0.00115	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000976	0.00113	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000969	0.00113	CcSEcCtD
Methsuximide—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00096	0.00112	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.00094	0.00109	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000925	0.00108	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000924	0.00107	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000918	0.00107	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000903	0.00105	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000897	0.00104	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000892	0.00104	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000888	0.00103	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000888	0.00103	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000856	0.000995	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.00085	0.000988	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000825	0.000959	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000821	0.000955	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—MET—peripheral nervous system neoplasm	0.000808	0.00591	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—ERBB2—peripheral nervous system neoplasm	0.000801	0.00586	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MET—peripheral nervous system neoplasm	0.000783	0.00572	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—peripheral nervous system neoplasm	0.000782	0.00572	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	0.00077	0.00563	CbGpPWpGaD
Methsuximide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000768	0.000893	CcSEcCtD
Methsuximide—CACNA1G—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.000747	0.00546	CbGpPWpGaD
Methsuximide—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000742	0.000863	CcSEcCtD
Methsuximide—CACNA1H—Axon guidance—PTPN11—peripheral nervous system neoplasm	0.000724	0.00529	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000723	0.00529	CbGpPWpGaD
Methsuximide—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000714	0.00083	CcSEcCtD
Methsuximide—Clobazam—ABCB1—peripheral nervous system neoplasm	0.000712	0.238	CrCbGaD
Methsuximide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000711	0.000826	CcSEcCtD
Methsuximide—Rash—Epirubicin—peripheral nervous system neoplasm	0.000708	0.000823	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000707	0.000822	CcSEcCtD
Methsuximide—Headache—Epirubicin—peripheral nervous system neoplasm	0.000703	0.000818	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000687	0.000799	CcSEcCtD
Methsuximide—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000667	0.000775	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000661	0.000768	CcSEcCtD
Methsuximide—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000655	0.000761	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000654	0.000761	CcSEcCtD
Methsuximide—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000651	0.000757	CcSEcCtD
Methsuximide—Phenytoin—ABCB1—peripheral nervous system neoplasm	0.000649	0.217	CrCbGaD
Methsuximide—Phenobarbital—ABCB1—peripheral nervous system neoplasm	0.000622	0.208	CrCbGaD
Methsuximide—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000617	0.000717	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—NRAS—peripheral nervous system neoplasm	0.00061	0.00446	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—ERBB2—peripheral nervous system neoplasm	0.000591	0.00432	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—peripheral nervous system neoplasm	0.000577	0.00422	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—ERBB2—peripheral nervous system neoplasm	0.000572	0.00418	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000572	0.00418	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—peripheral nervous system neoplasm	0.000559	0.00408	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000533	0.0039	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PTPN11—peripheral nervous system neoplasm	0.000517	0.00378	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000484	0.00354	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—peripheral nervous system neoplasm	0.000449	0.00329	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—peripheral nervous system neoplasm	0.000446	0.00326	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—peripheral nervous system neoplasm	0.000435	0.00318	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000435	0.00318	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000422	0.00308	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ERBB2—peripheral nervous system neoplasm	0.000408	0.00298	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—peripheral nervous system neoplasm	0.000329	0.0024	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000321	0.00234	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000319	0.00233	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—peripheral nervous system neoplasm	0.000318	0.00233	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—peripheral nervous system neoplasm	0.000318	0.00233	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—peripheral nervous system neoplasm	0.000311	0.00227	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—peripheral nervous system neoplasm	0.000281	0.00205	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—peripheral nervous system neoplasm	0.000235	0.00172	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—peripheral nervous system neoplasm	0.000227	0.00166	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000216	0.00158	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—peripheral nervous system neoplasm	0.000207	0.00151	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—peripheral nervous system neoplasm	0.000201	0.00147	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000179	0.00131	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GNS—peripheral nervous system neoplasm	0.000156	0.00114	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—NME1—peripheral nervous system neoplasm	0.000149	0.00109	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—COX2—peripheral nervous system neoplasm	0.000144	0.00105	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	9.44e-05	0.00069	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	7.98e-05	0.000583	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.61e-05	0.000557	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	7.5e-05	0.000548	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	6.12e-05	0.000448	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	6.01e-05	0.000439	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	1.65e-05	0.000121	CbGpPWpGaD
